Pulmonary arterial hypertension: a pharmacotherapeutic update

JC Coons, K Pogue, AR Kolodziej, GA Hirsch… - Current cardiology …, 2019 - Springer
Abstract Purpose of Review Pulmonary arterial hypertension (PAH) leads to progressive
increases in pulmonary vascular resistance (PVR), right heart failure, and death if left …

TGF‐β/Smads signaling pathway, Hippo‐YAP/TAZ signaling pathway, and VEGF: Their mechanisms and roles in vascular remodeling related diseases

H Liu, M Sun, N Wu, B Liu, Q Liu… - Immunity, Inflammation …, 2023 - Wiley Online Library
Vascular remodeling is a basic pathological process in various diseases characterized by
abnormal changes in the morphology, structure, and function of vascular cells, such as …

Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension

L Tu, A Desroches-Castan, C Mallet, L Guyon… - Circulation …, 2019 - Am Heart Assoc
Rationale: Although many familial cases of pulmonary arterial hypertension exhibit an
autosomal dominant mode of inheritance with the majority having mutations in essential …

Mice with a specific deficiency of Pfkfb3 in myeloid cells are protected from hypoxia‐induced pulmonary hypertension

L Wang, X Zhang, Y Cao, Q Ma, X Mao… - British Journal of …, 2021 - Wiley Online Library
Background and Purpose Macrophage infiltration into the lungs is a characteristic of
pulmonary hypertension (PH). Glycolysis is the main metabolic pathway for macrophage …

Aldehyde Dehydrogenase 2 (ALDH2) Elicits Protection against Pulmonary Hypertension via Inhibition of ERK1/2‐Mediated Autophagy

S Chang, J Wu, J Jin, H Shi, R Gao, X Li… - Oxidative medicine …, 2022 - Wiley Online Library
Pulmonary hypertension (PH) is caused by chronic hypoxia that induces the migration and
proliferation of pulmonary arterial smooth muscle cells (PASMCs), eventually resulting in …

Endothelial basement membrane components and their products, matrikines: active drivers of pulmonary hypertension?

AC Mutgan, K Jandl, G Kwapiszewska - Cells, 2020 - mdpi.com
Pulmonary arterial hypertension (PAH) is a vascular disease that is characterized by
elevated pulmonary arterial pressure (PAP) due to progressive vascular remodeling …

SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension

Y Yao, H Li, X Da, Z He, B Tang, Y Li, C Hu… - Pulmonary …, 2019 - Elsevier
Introduction Pulmonary arterial hypertension (PAH) is a life-threatening disease without
effective therapies. PAH is associated with a progressive increase in pulmonary vascular …

Nets, pulmonary arterial hypertension, and thrombo-inflammation

LP Baptista de Barros Ribeiro Dourado… - Journal of Molecular …, 2022 - Springer
Pulmonary arterial hypertension (PAH) is a progressive and fatal vascular disease in which
high blood pressure in the pulmonary artery and remodeling of the pulmonary vasculature …

Down-regulation of miR-204 attenuates endothelial-mesenchymal transition by enhancing autophagy in hypoxia-induced pulmonary hypertension

T Liu, XZ Zou, N Huang, XY Ge, MZ Yao, H Liu… - European Journal of …, 2019 - Elsevier
Pulmonary arterial remodeling is a crucial cause of increased pulmonary artery pressure
during pulmonary hypertension (PH). Recently, growing evidence has upheld the …

LncPTSR Triggers Vascular Remodeling in Pulmonary Hypertension by Regulating [Ca2+]i in Pulmonary Arterial Smooth Muscle Cells

L Deng, J Chen, B Chen, T Wang, L Yang… - American Journal of …, 2022 - atsjournals.org
Pulmonary hypertension (PH) is characterized by vascular remodeling and sustained
increase in right ventricular systolic pressure. The molecular mechanisms behind PH …